# Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)

> **NCT02245503** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 7391 (actual)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** Tamsulosin

## Key facts

- **NCT ID:** NCT02245503
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2003-10
- **Final completion:** —
- **Target enrollment:** 7391 (ACTUAL)
- **Last updated:** 2014-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02245503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02245503, "Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02245503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*